Improving outcomes in umbilical cord blood transplantation: State of the art

Blood Reviews

Volumn 26, Issue 6, 2012, Pages 241-246

  Cutler, Corey ^a   Ballen, Karen K ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Transplantation; Umbilical cord blood

Indexed keywords

ARTICLE; BONE MARROW TRANSPLANTATION; CELL HOMING; CELL SELECTION; CORD BLOOD STEM CELL TRANSPLANTATION; ENGRAFTMENT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; STEM CELL EXPANSION; UMBILICAL CORD BLOOD;

CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; HEMATOLOGIC NEOPLASMS; HUMANS; TREATMENT OUTCOME;

EID: 84868699310     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.08.001     Document Type: Article

References (62)

1. Ballen K.K., King R.J., Chitphakdithai P., Bolan C.D., Agora E., Hartzman R.J., et al. The National Marrow Donor Program experience: the first 20 years of unrelated donor stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:2-7.
2. Ballen K.K., Barker J.N., Stewart S.K., Greene M.F., Lane T.A. Collection and preservation of cord blood for personal use. Biol Blood Marrow Transplant 2008, 14:356-363.
3. Laskey L.C., Lane T., Miller J., Lindgren B., Patterson H., Haley N.R., et al. In utero or ex utero cord blood collection: which is better?. Transfusion 2002, 42:1261-1267.
4. Chow R., Nademanee A., Rosenthal J., Karanes C., Jaing T.H., Graham M.L., et al. Analysis of hematopoietic cell transplants using plasma-depleted cord blood products that are not red blood cell reduced. Biol Blood Marrow Transplant 2007, 13:1346-1357.
5. Gluckman E., Broxmeyer H.A., Auerbach A.D., Friedman H.S., Douglas G.W., Devergie A., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 1989, 321:1174-1178.
6. Eapen M., Rubinstein P., Zhang M.J., Stevens C., Kurtzberg J., Scaradavou A., et al. Outcomes of transplantation of unrelated umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Lancet 2007, 369:1947-1954.
7. Bachanova V., Burke M.J., Yohe S., Cao Q., Sandhu K., Singleton T.P., et al. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant 2012, 18:963-968.
8. Ruggeri A., Eapen M., Scaravadou A., Cairo M.S., Bhatia M., Kurtzberg J., et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011, 17:1375-1382.
9. Prasad V.K., Mendizabal A., Parikh S.H., Szabolcs P., Driscoll T.A., Page K., et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 2008, 112:2979-2989.
10. Laughlin M.J., Eapen M., Rubinstein P., Wagner J.E., Zhang M.J., Champlin R.E., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
11. Ooi J., Takahashi S., Tomonari A., Tsukada N., Konuma T., Kato S., et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogeneous leukemia. Biol Blood Marrow Transplant 2008, 14:1341-1347.
12. Cohen Y.C., Scaradavou A., Stevens C.E., Rubinstein P., Gluckman E., Rocha V., et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant 2011, 46:70-76.
13. Brunstein C.G., Barker J.N., Weisdorf D.J., DeFor T.E., Miller J.S., Blazar B.R., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
14. Ballen K.K., Spitzer T.R., Yeap B.Y., McAfee S., Dey B.R., Attar E., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007, 13:82-89.
15. Cutler C., Stevenson K., Kim H.T., Brown J., McDonough S., Herrera M., et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus based GVHD prophylaxis. Bone Marrow Transplant 2011, 46:273-277.
16. MacMillan M.L., Weisdorf D.J., Brunstein C.G., Cao Q., DeFor T.E., Verneris M.R., et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009, 113:2410-2415.
17. Verneris M.R., Brunstein C.G., Barker J., MacMillan M.L., DeFor T., McKenna D.H., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
18. Frassoni F., Gualandi F., Podestá M., Raiola A.M., Ibatici A., Piaggio G., et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008, 9:831-839.
19. Brunstein C.G., Barker J.N., Weisdorf D.J., Defor T.E., McKenna D., Chong S.Y., et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant 2009, 43:935-940.
20. Delaney C., Varnum-Finney B., Aoyama K., Brashem-Stein C., Bernstein I.D. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 2005, 106:2693-2699.
21. Delaney C., Heimfeld S., Brashem-Stein C., Voorhies H., Manger R.L., Bernstein I.D. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010, 16:232-236.
22. de Lima M., Robinson S., McMannis J., Alousi A.M., Saliba R.M., Munsell M., et al. Mesenchymal stem cell (MSC) based cord blood (CB) expansion (Exp) leads to rapid engraftment of platelets and neutrophils. ASH Annu Meet Abstr 2010, 116:362.
23. Peled T., Landau E., Prus E., Treves A.J., Nagler A., Fibach E. Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. Br J Haematol 2002, 116:655-661.
24. Peled T., Glukhman E., Hasson N., Adi S., Assor H., Yudin D., et al. Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells. Exp Hematol 2005, 33:1092-1100.
25. Snyder D., Landau E., Rosenheimer N., Mandel J., Glukhman E., Hasson N., et al. StemEx® is expanding: pivotal trial nears completion, and development of a cryopreserved product is underway. Biol Blood Marrow Transplant 2012, 18:s260-s261.
26. Peled T., Shoham H., Aschengrau D., Yackoubov D., Frei G., Nagler A., et al. Nicotinamide, a recognized inhibitor of SIRT1, promotes expansion in ex vivo cultures of short and long-term repopulating cells. ASH Annu Meet Abstr 2009, 114:2431.
27. Horwitz M., Chao N.J., Rizzieri D., Long G.D., Sullivan K.M., Gasparetto C., et al. NiCord® expanded haematopoietic progenitor cells are capable of prolonged myeloid and lymphoid engraftment following myeloablative dual umbilical cord blood transplantation. Bone Marrow Transplant 2012, 47:s57.
28. Boitano A.E., Wang J., Romeo R., Bouchez L.C., Parker A.E., Sutton S.E., et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010, 329:1345-1348.
29. Blank U., Ehrnstrom B., Heinz N., Nilsson E., Brun A., Baum C., et al. Angptl4 maintains in vivo repopulation capacity of CD34+ human cord blood cells. Eur J Haematol 2012, 89:198-205.
30. Broxmeyer H.E., Srour E.F., Cooper S., Wallace C.T., Hangoc G., Youn B.S. Angiopoietin-like-2 and -3 act through their coiled-coil domains to enhance survival and replating capacity of human cord blood hematopoietic progenitors. Blood Cells Mol Dis 2012, 48:25-29.
31. Ko K.H., Holmes T., Palladinetti P., Song E., Nordon R., O'Brien T.A., et al. GSK-3+ inhibition promotes engraftment of ex vivo-expanded hematopoietic stem cells and modulates gene expression. Stem Cells 2011, 29:108-118.
32. Tanaka H., Matsumura I., Itoh K., Hatsuyama A., Shikamura M., Satoh Y., et al. HOX decoy peptide enhances the ex vivo expansion of human umbilical cord blood CD34+ hematopoietic stem cells/hematopoietic progenitor cells. Stem Cells 2006, 24:2592-2602.
33. Ballen KK, Mendizibal AM, Cutler C, et al. Phase II Trial of parathyroid hormone after double umbilical cord blood transplantation. Biology Blood Marrow Transplant in press. [2012 Jul 2, Electronic publication ahead of print].
34. Campbell T.B., Hangoc G., Liu Y., Pollok K., Broxmeyer H.E. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev 2007, 16:347-354.
35. Farag S. Inhibition of CD26/DPP4 for enhancing engraftment of single cord blood units in adults with leukemia. International Cord Blood Symposium Abstract Booklet 2012.
36. Ratajczak M.Z., Reca R., Wysoczynski M., Yan J., Ratajczak J. Modulation of the SDF-1-CXCR4 axis by the third complement component (C3)-implications for trafficking of CXCR4+ stem cells. Exp Hematol 2006, 34:986-995.
37. Wysoczynski M., Reca R., Lee H., Wu W., Ratajczak J., Ratajczak M.Z. Defective engraftment of C3aR-/- hematopoietic stem progenitor cells shows a novel role of the C3a-C3aR axis in bone marrow homing. Leukemia 2009, 23:1455-1461.
38. Ratajczak J., Reca R., Kucia M., Majka M., Allendorf D.J., Baran J.T., et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 2004, 103:2071-2078.
39. Brunstein C.G., McKenna D., Defor T.E., Sumstad D., Ratajczak M., Laughlin M.J., et al. Priming of hematopoietic progenitor cells (HPC) with complement fragment 3A (C3A) to promote homing of umbilical cord blood (UCB): safety profile. Biol Blood Marrow Transplant 2012, 18:s210.
40. Cutler C.S., Shoemaker D., Ballen K.K., Robbins D., Desponts C., Kao G.S., et al. FT1050 (16,16-dimethyl prostaglandin E2)-enhanced umbilical cord blood accelerates hematopoietic engraftment after reduced intensity conditioning and double umbilical cord blood transplantation. ASH Annu Meet Abstr 2011, 118:653.
41. Taupin P. Ex vivo fucosylation to improve the engraftment capability and therapeutic potential of human cord blood stem cells. Drug Discov Today 2010, 15:698-699.
42. Barker J.N., Scaradavou A., Stevens C.E. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2011, 115:1843-1849.
43. Delaney M., Cutler C.S., Haspel R.L., Yeap B.Y., McAfee S.L., Dey B.R., et al. High-resolution HLA matching in double-umbilical-cord blood reduced intensity transplantation in adults. Transfusion 2009, 49:995-1002.
44. Delaney M., Ballen K.K. The role of HLA in umbilical cord blood transplantation. Best Pract Res Clin Haematol 2010, 23:179-187.
45. van Rood J.J., Stevens C.E., Smits J. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematologic malignancies. Proc Natl Acad Sci 2009, 106:19952-19957.
46. Eapen M., Klein J.P., Sanz G.F., Spellman S., Ruggeri A., Anasetti C, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukemia and myelodysplastic syndromde: a retrospective analysis. Lancet Oncol 2011, 12:1214-1221.
47. Cutler C., Kim H.T., Sun L., et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011, 118:6691-6697.
48. Ballen K.K., Klein J.P., Pedersen T.L., Bhatia D., Duerst R., Kurtzberg J., et al. Relationship of race/ethnicitiy and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2012, 18:903-912.
49. Rocha V., Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose, and other graft-and transplantation-related factors. Br J Hematol 2009, 147:262-274.
50. Eapen M., Rocha V., Sanz G., Scaradavou A., Zhang M.J., Arcese W., et al. Effect of graft source on unrelated donor hematopoietic stem-cell transplantation in adults with acute leukemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660.
51. Brunstein C.G., Gutman J.A., Weisdorf D.J., Woolfrey A.E., Defor T.E., Gooley T.A., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
52. Chen Y.B., Aldridge J., Kim H.T., Ballen K.K., Cutler C., Kao G., et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant 2012, 18:805-812.
53. Brunstein C.G., Fuchs E.J., Carter S.L., Karanes C., Costa L.J., Wu J., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
54. Brunstein C.G., Eapen M., Ahn K.W., Appelbaum F.R., Ballen K.K., Champlin R.E., et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012, 119:5591-5598.
55. Bautista G., Cabrera J.R., Regidor C., Forés R., García-Marco J.A., Ojeda E., et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third party donor. Bone Marrow Transplant 2009, 43:365-373.
56. Liu H., Rich E.S., Godley L., Odenike O., Joseph L., Marino J.S., et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011, 118:6438-6445.
57. Zhao Y., Jiang Z., Zhao T., Ye M., Hu C., Yin Z., et al. Reversal of type I diabetes via islet B cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BioMed Cent Med 2012, 10:3-11.
58. Rosenkranz K., Kumbruch S., Tenbusch M., Marcus K., Marschner K., Dermietzel R., et al. Transplantation of human umbilical cord blood cells mediated beneficial effects on apoptosis, angiogenesis, and neuronal survival after hypoxic-ischemic brain injury in rats. Cell Tissue Res 2012, 348:429-438.
59. Roura S., Pujal J.M., Bayes-Genis A., et al. Umbilical cord blood for cardiovascular cell therapy: from promise to fact. Ann N Y Acad Sci 2012, 1254:66-70.
60. Aversa F., Terenzi A., Tabilio A., Falzetti F., Carotti A., Ballanti S., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
61. Huang X.J., Liu D.H., Liu K.Y. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:257-265.
62. Nakamae H., Storer B.E., Storb R., Storek J., Chauncey T.R., Pulsipher M.A., et al. Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. Biol Blood Marrow Transplant 2010, 16:384-394.